drugset / Trial / NCT02278276

Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients

NCT02278276 ↗

Phase 1/2 Unknown 50 enrolled Sulfagenix Australia Pty Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and benefits of SG1002, including overcoming deficits in circulating hydrogen sulfide and nitrite found in heart failure patients, with secondary endpoints focused on improving clinical endpoints.

Timeline

Start
2016-04
Primary completion
2018-04
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator sodium polysulthionate Unknown 800 mg —

Indications